Report
Smart Bet, Only Option, or Both? Biopharma R&D Turns to AI.
Facing rising drug-development costs and high clinical failure rates, biopharma companies are turning to AI to improve R&D productivity. AI is already supporting target identification, molecule design, trial planning, regulatory submissions and predictive analysis, with many organizations reporting measurable time savings. Most industry executives expect AI to transform R&D, and nearly three in ten organizations are piloting AI agents. Scaling these capabilities will require stronger data quality and integration, leadership support, clear risk frameworks, external partnerships and a workforce equipped with both scientific and digital skills.
